Merrill maintains Amylin at neutral

Amylin Pharmaceuticals, Inc. was maintained at neutral by Merrill Lynch analysts Thomas McGahren, Eric Ende and David Munno after the company announced the start of a long-term comparator trial of exenatide long-acting release for type 2 diabetes. Merrill said it is unclear if the trial, announced with Eli Lilly & Co. and Alkermes Inc. will be sufficient for a New Drug Application, noting that its assumption of a 2009 launch for the drug is unchanged. Shares of the San Diego-based biopharmaceutical company were down $1.44, or 3.08%, to $45.34 on volume of 1,799,261 shares versus the three-month running average of 2,075,261 shares. (Nasdaq: AMLN)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.